Financial Performance - The company's revenue for Q1 2025 was CNY 2,477,948,927.49, representing a 5.42% increase compared to CNY 2,350,478,362.11 in the same period last year[4] - Net profit attributable to shareholders was CNY 370,082,216.76, a 1.87% increase from CNY 363,297,720.56 year-on-year[4] - The net profit after deducting non-recurring gains and losses increased by 26.09% to CNY 378,502,314.92 from CNY 300,194,937.03 in the previous year[4] - Basic earnings per share for Q1 2025 was ¥0.45, up from ¥0.44 in Q1 2024[17] - The total comprehensive income for Q1 2025 was ¥363,235,743.84, slightly up from ¥362,987,690.02 in Q1 2024[16] Cash Flow - The net cash flow from operating activities improved to -CNY 353,474,219.65, compared to -CNY 657,050,656.93 in the same period last year[4] - Cash flow from operating activities in Q1 2025 was negative at -¥353,474,219.65, an improvement from -¥657,050,656.93 in Q1 2024[18] - The net cash flow from investment activities was 1,123,792,938.39 in the previous period[19] - The net cash flow from financing activities was -52,965,585.80 in the previous period, indicating a reduced outflow[19] Assets and Liabilities - The total assets at the end of the reporting period were CNY 28,846,018,517.29, a 2.89% increase from CNY 28,035,688,872.48 at the end of the previous year[5] - The company's total liabilities increased to RMB 8,563,210,960.39 from RMB 8,129,447,799.81, which is an increase of about 5.3%[13] - The equity attributable to shareholders reached RMB 20,284,291,823.43, up from RMB 19,903,165,417.53, reflecting a growth of approximately 1.9%[13] - The company's current assets totaled RMB 21,178,583,764.62, compared to RMB 20,893,841,318.46 at the end of 2024, indicating an increase of about 1.37%[12] Research and Development - Research and development expenses totaled CNY 567,853,212.94, up 12.01% from CNY 506,949,927.30, accounting for 22.92% of total revenue[5] - Research and development expenses for Q1 2025 were ¥378,872,051.95, down 9.7% from ¥419,681,857.09 in Q1 2024[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 21,435[8] - The company received government subsidies amounting to CNY 17,600,465.75 during the period[6] Inventory and Receivables - The company's inventory increased to RMB 6,137,986,392.11 from RMB 5,528,382,408.16, indicating a rise of about 11%[11] - Accounts receivable rose to RMB 4,907,131,343.58 from RMB 4,358,808,221.15, marking an increase of around 12.6%[11] Cash and Cash Equivalents - The cash and cash equivalents decreased to RMB 7,185,525,069.64 from RMB 8,399,997,063.38, representing a decline of approximately 14.5%[11] - The cash and cash equivalents at the end of the period were 5,867,855,094.11 at the beginning of the period[19] - The company’s cash and cash equivalents decreased by $321,098,553.19 during the period[19] Other Financial Metrics - The weighted average return on equity decreased slightly to 1.84% from 1.91%[5] - Operating profit for Q1 2025 was ¥398,763,564.24, compared to ¥400,407,296.57 in Q1 2024, indicating a decrease of 0.4%[16] - Total operating costs for Q1 2025 were ¥2,132,796,705.76, an increase of 3.8% from ¥2,055,132,564.46 in Q1 2024[15] - Other income for Q1 2025 was ¥115,812,587.45, compared to ¥105,262,737.48 in Q1 2024, reflecting an increase of 10.5%[15] Future Outlook - The company plans to implement new accounting standards starting in 2025, which may affect the financial statements[19]
联影医疗(688271) - 2025 Q1 - 季度财报